Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon

Table 6 Killer immunoglobulin receptor gene expression and levels of anti-HBs among the vaccinated study participants n (%)

KIR genes	Group I1 (n = 36)	Group II2 (n = 16)	Group III3 (n = 15)	Group IV4 (n = 7)	Test5	P value
2DL2	17 (47.20)	10 (62.50)	11 (73.30)	3 (42.90)	FET	0.362
2DL3	31 (86.10)	14 (87.50)	12 (80.00)	6 (85.70)	FET	0.824
2DL5A	9 (25.00)	4 (25.00)	4 (26.70)	4 (57.10)	FET	0.987
2DL5B	9 (25.00)	10 (62.50)	4 (26.70)	1 (14.30)	FET	0.0236
2DS1	11 (30.60)	8 (50.00)	7 (46.70)	4 (57.10)	FET	0.530
2DS2	16 (44.40)	10 (62.50)	11 (73.30)	3 (42.90)	FET	0.270
2DS3	12 (33.30)	11 (68.80)	8 (53.30)	1 (14.30)	5.01	0.060
2DS4*001/002	15 (41.70)	5 (31.30)	6 (40.00)	2 (28.60)	0.568	0.920
2DS4*003/007	28 (77.80)	13 (81.30)	13 (86.70)	6 (85.70)	FET	0.860
2DS5	11 (30.60)	6 (37.50)	6 (40.00)	3 (42.90)	0.846	0.850
3DS1	14 (38.90)	7 (43.80)	7 (46.70)	6 (85.70)	FET	0.960
2DL4	36 (100.00)	16 (100.00)	15 (100.00)	4 (57.10)	0.258	0.970
3DP*001/002/004	8 (22.20)	1 (6.30)	4 (26.70)	1 (14.30)	FET	0.420

¹Group I: Vaccinated participants and anti-HBs titers > 100 mIU/mL;

²Group II: Vaccinated participants and anti-HBs titers 10-100 mIU/mL;

³Group III: Vaccinated participants and anti-HBs titers 0.1-9.99 mIU/mL;

⁴Group IV: Vaccinated participants and anti-HBs titers = 0 mIU/mL;

⁵The statistical test performed to compare the frequencies of KIR gene expression among the vaccinated study participants whereby FET refers to Fisher’s exact test and the rest of the values represent the Pearson χ² value;

⁶Significant difference of KIR2DL5B expression among vaccinated study participants (P < 0.05). KIR: Killer immunoglobulin receptor; FET: Fisher-exact test.